HopeStage
Back to all studies
CompletedNCT02501109

Aripiprazole Oral Film Compared With Tablet in Healthy Adults

About this titleRead the official source — NCT02501109
Medication studyAges 45–65Schizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for healthy volunteers. Listed age limits: 45 years to 65 years. Other eligibility criteria applied.

Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2015
Recruitment status
Completed
Enrollment listed in the registry
36
Sponsor
CMG Pharmaceutical Co. Ltd
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Not clearly listed
Age range
From 45 Years to 65 Years
Official registry ID
NCT02501109
Official title
Show the full official title

A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify® 10 mg Tablet in Healthy Volunteers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is CMG Pharmaceutical Co. Ltd, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 45 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies